Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ISRCTN49366748) titled 'A phase II study to test the safety and effects of BC-006 Injection in adults with obesity' on April 13.
Study Type: Interventional
Study Design:
Allocation: Randomized controlled trial
Masking: Blinded (masking used)
Control: Placebo
Assignment: Parallel
Purpose: Treatment
Primary Sponsor: BaseCure Therapeutics Inc.
Condition:
Obesity
Nutritional, Metabolic, Endocrine
Intervention:
This is a Phase IIa, randomized, double-blind, placebo-controlled trial designed to evaluate the safety, tolerability, PK, PD, and efficacy of BC-006 administered via subcutaneous injection (SC) in adults with obesity. The stud...